Want to see HK:9955 full AI Analyst Report?
9955 Stock Chart & Stats
HK$1.00
HK$0.03(2.52%)
At close: 4:00 PM EST
HK$1.00
HK$0.03(2.52%)
Day’s Range― - ―
52-Week RangeHK$0.45 - HK$1.44
Previous CloseN/A
Volume146.50K
Average Volume (3M)114.53K
Market Cap
HK$286.33M
Enterprise ValueHK$83.79M
Total Cash (Recent Filing)HK$442.74M
Total Debt (Recent Filing)HK$210.16M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Mar 25, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.65
Shares Outstanding645,718,800
10 Day Avg. Volume72,350
30 Day Avg. Volume114,534
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.00
Price to Sales (P/S)0.34
P/FCF Ratio-8.40
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.11
Revenue Forecast (FY)HK$7.73B
Bulls Say, Bears Say
Bulls Say
Improved Gross MarginGross margin rose to about 48% in 2025 from roughly 25% in 2023–2024, indicating materially better product economics. If retained, this improvement can provide more contribution per sale and create a stronger base for eventual operating leverage, even though profitability remains negative.
Positive Operating Cash FlowOperating cash flow swung to approximately 82M in 2025 after being negative in each of 2021–2024. This is an important improvement in cash conversion and may reduce reliance on external funding, although it needs to persist before it can be viewed as a durable self-funding model.
Balance Sheet StabilizationEquity remained positive from 2022 through 2025, while 2025 debt-to-equity of about 0.53 was described as more normalized than the negative-equity period in 2020–2021. This stabilization gives the company a stronger capital base for navigating losses and funding operations.
Bears Say
Revenue ContractionRevenue fell about 30% in 2025, following a more modest decline in 2024 and reversing strong growth in 2022–2023. Persistent contraction weakens scale, reduces the opportunity to spread fixed costs, and makes the improved gross margin harder to convert into sustainable earnings.
Persistent Net LossesNet losses remained very large in 2025, with net margin around negative 57%, while operating losses also continued despite the gross-margin improvement. This shows that product-level economics have not yet translated into company-wide profitability, leaving capital and future reinvestment capacity under pressure.
Negative Free Cash FlowFree cash flow was about negative 65M in 2025 despite positive operating cash flow, and the company had recorded sizable operating cash burn in multiple prior years. Continued investment and working-capital demands therefore prevent the business from being demonstrably self-funding and make cash consistency a material concern.
ClouDr Group Limited News
9955 FAQ
What was ClouDr Group Limited’s price range in the past 12 months?
ClouDr Group Limited lowest stock price was HK$0.45 and its highest was HK$1.44 in the past 12 months.
What is ClouDr Group Limited’s market cap?
ClouDr Group Limited’s market cap is HK$286.33M.
When is ClouDr Group Limited’s upcoming earnings report date?
ClouDr Group Limited’s upcoming earnings report date is Mar 25, 2027 which is in 162 days.
How were ClouDr Group Limited’s earnings last quarter?
ClouDr Group Limited released its earnings results on Aug 27, 2026. The company reported -HK$0.054 earnings per share for the quarter.
Is ClouDr Group Limited overvalued?
According to Wall Street analysts ClouDr Group Limited’s price is currently Overvalued.
Does ClouDr Group Limited pay dividends?
ClouDr Group Limited does not currently pay dividends.
What is ClouDr Group Limited’s EPS estimate?
ClouDr Group Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ClouDr Group Limited have?
ClouDr Group Limited has 645,718,800 shares outstanding.
What happened to ClouDr Group Limited’s price movement after its last earnings report?
ClouDr Group Limited reported an EPS of -HK$0.054 in its last earnings report. Following the earnings report the stock price went up 3.03%.
Which hedge fund is a major shareholder of ClouDr Group Limited?
Currently, no hedge funds are holding shares in HK:9955
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ClouDr Group Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.75%
12-Months-Change
Fundamentals
Return on Equity
-76.42%
Trailing 12-Months
Asset Growth
-28.07%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
ClouDr Group Limited
ClouDr Group Limited operates as an investment holding company, providing a diverse range of services within the healthcare sector. The firm supplies hospitals and pharmacies with crucial medical products, including devices like blood glucose meters and vital sign monitors, glucose testing strips, and both over-the-counter and prescription drugs. In addition to physical goods, ClouDr delivers software-as-a-service (SaaS) platforms tailored for healthcare facilities and pharmacies, while also offering digital marketing solutions to pharmaceutical companies. Furthermore, the company facilitates the management of chronic conditions through real-time online consultations, digital health monitoring, and remote prescription and ordering services. Established in 2014, ClouDr Group Limited maintains its primary corporate office in Hangzhou, China.
Technical Analysis
China Health Group
―
Sinopharm Group Co
―
IVD Medical Holding Limited
―
Medlive Technology Co., Ltd.
―
Charmacy Pharmaceutical Co., Ltd. Class H
―